Another Alzheimer’s failure: Axovant’s drug flops in late-stage trial
Axovant's experimental drug, intepirdine, was not seen as a cure for Alzheimer's; the goal was simply to delay progression. But it failed to do that.
Yet another once-promising treatment for Alzheimer’s disease has come up short in the final stage of development, this time adding Wall Street drama to the familiar disappointment that has plagued the drug industry for decades.
A pill called intepirdine, developed by the biotech startup Axovant Sciences, failed to blunt the symptoms of Alzheimer’s in a large trial. The drug was never seen as a cure, but the company had hoped
